Saturday, March 2, 2024

CATEGORY

Sanofi

FDA Priority Review for Breakthrough Biologic Therapy: Dupixent Eyes New Frontier in COPD Treatment

Regeneron Pharmaceuticals and Sanofi have announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application...

Sanofi Faces Lawsuit Over Contaminated Rare Disease Treatment After 12 Years

A federal court in Massachusetts has rekindled a lawsuit that has been dormant for nearly twelve years, targeting Sanofi for its alleged role in...

Chronic Spontaneous Urticaria Treatment Dupixent® Approved in Japan

Japan has emerged as a pioneer in the global healthcare landscape by granting the first-ever approval for Dupixent® (dupilumab) to treat chronic spontaneous urticaria...

Beyfortus Receives Approval in China for Infant Respiratory Syncytial Virus Disease Prevention

AstraZeneca and Sanofi's nirsevimab, commercially known as Beyfortus, has gained approval in China for averting lower respiratory tract infections (LRTIs) caused by respiratory syncytial...

EMA Grants Positive Opinion for Fexinidazole Treatment for Sleeping Sickness

Sanofi, DNDi (Drugs for Neglected Diseases Initiative), and the HAT-r-ACC consortium have announced a significant breakthrough in the fight against sleeping sickness. The European...

FTC Challenges Sanofi’s Pompe Disease Treatment Licensing Deal Over Monopoly Concerns

The Federal Trade Commission (FTC) is opposing Sanofi's planned $755 million agreement to license Maze Therapeutics' clinical-stage Pompe disease treatment. According to the FTC,...

Sanofi’s Consumer Healthcare Unveils Shared Care Collective to Drive Sustainability Initiatives

Sanofi’s Consumer Healthcare business unit unveiled the Shared Care Collective, a groundbreaking initiative launched on December 1, 2023. This pioneering advisory board comprises a...

Dupixent®’s Positive Phase 3 Trial for COPD Spurs FDA Submission as Potential First Approved Biologic

The NOTUS trial, the second Phase 3 trial for Dupixent®, has reported a 34% reduction in chronic obstructive pulmonary disease (COPD) exacerbations, supporting previous...

Sanofi Successfully Concludes Development for Innovative Extraintestinal Pathogenic E. Coli Vaccine

Sanofi has successfully concluded the closing of its collaboration with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to jointly develop and market a...

Sanofi Achieves Milestone: Closes Potential First-in-Class Vaccine for Extraintestinal Pathogenic E.coli

Sanofi has successfully concluded the closure of its collaborative agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, marking a significant step...

Latest news

Sticky Image